Fri Oct 04 05:58:43 UTC 2024: ## AbbVie (ABBV) Updates Earnings Guidance, Analysts Remain Bullish

**New York, NY (October 4, 2024)** – AbbVie (NYSE:ABBV) has adjusted its third-quarter 2024 earnings guidance, with the company now expecting EPS of $2.920-$2.960. This falls slightly below the consensus analyst estimate of $2.950. While the company has yet to provide specific revenue guidance, it has revised its full-year 2024 EPS guidance to $10.710-$10.910.

Despite the slight adjustment in third-quarter guidance, analysts remain optimistic about AbbVie’s prospects. Recent reports from several investment firms, including Cantor Fitzgerald, Truist Financial, Morgan Stanley, William Blair, and Piper Sandler Companies, have reiterated their bullish sentiment.

The consensus rating for AbbVie currently stands at “Buy” with a price target of $191.64, according to MarketBeat. This positive outlook is further reinforced by AbbVie’s strong second-quarter earnings results, where the company exceeded analysts’ expectations for both earnings per share and revenue.

AbbVie continues to impress with its strong performance and robust pipeline. The company’s dividend remains attractive, with a quarterly payout of $1.55, representing a yield of 3.17%.

**Insider Trading:**

Chairman Richard A. Gonzalez has sold a significant amount of AbbVie stock in recent months, triggering some investor concerns. However, these sales are unlikely to impact AbbVie’s overall performance or long-term growth trajectory.

**Looking Forward:**

Investors will be closely watching AbbVie’s upcoming earnings releases for further insight into the company’s future performance. The company’s strong growth trajectory, coupled with its diverse portfolio of products and promising pipeline, suggests continued success in the pharmaceutical industry.

Read More